TP53 and breast cancer: Taken together, one possible explanation is that initially luminal-like gBRCA2-mutated breast cancer are affected by TP53 co-mutation to become closer to basal-like entities, and more sensitive to neoadjuvant and adjuvant chemotherapy that led to less distant metastases and deaths.